The FDA approval covers a single 300 mg dose of Imjudo given alongside 1,500 mg Imfinzi, followed by Imfinzi every four weeks – known as the STRIDE (single tremelimumab regular interval ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

AstraZeneca's PD-L1 inhibitor Imfinzi has become the immunotherapy to be approved in the US for limited-stage small cell lung cancer (LS-SCLC), a particularly challenging form of the disease.

Mounjaro’s typical starting dosage is 2.5 milligrams (mg) once per week for 4 weeks, after which your doctor may increase the dose to 5 mg per week if needed to manage blood sugar levels.